![Ian Ying Woo](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Ian Ying Woo
Präsident bei
EVEREST MEDICINES LIMITED
Vermögen: 3 Mio $ am 31.08.2026
Profil
Ian Ying Woo is currently President, CFO & Executive Director at Everest Medicines Ltd. since 2022, and Executive Director at Everest Medicines (US) Ltd. and Everest Medicines II Ltd. Mr. Woo is also Director at NovaBridge Biosciences starting in 2025 and Operating Partner at CBC Group Co., Ltd. since 2019.
Former roles include Managing Director at Lazard Frères & Co. LLC and Independent Director at Prenetics Global Ltd. Education includes an undergraduate degree from Tufts University in 1994, a graduate degree from the Graduate School of Arts & Sciences at Columbia University in 1998, and an MBA from Columbia Business School in 2003.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
EVEREST MEDICINES LTD. 0,23 % | 30.06.2026 | 820.633 ( 0,23 % ) | 3 Mio $ | 31.08.2026 |
Aktive Positionen von Ian Ying Woo
| Unternehmen | Position | Beginn |
|---|---|---|
| EVEREST MEDICINES LIMITED | Präsident | 01.12.2018 |
| NOVABRIDGE BIOSCIENCES | Direktor/Vorstandsmitglied | 30.10.2025 |
CBC Group Co., Ltd. | Corporate Officer/Principal | 01.06.2018 |
Everest Medicines II Ltd.
 Everest Medicines II Ltd. Pharmaceuticals: MajorHealth Technology Develops and commercializes pharmaceutical products | Direktor/Vorstandsmitglied | - |
Everest Medicines (US) Ltd.
 Everest Medicines (US) Ltd. Pharmaceuticals: MajorHealth Technology Part of Everest Medicines Ltd., Everest Medicines (US) Ltd. is a biopharmaceutical company focused on developing and commercializing pharmaceutical products that address unmet medical needs for patients in Asian markets. The company is based in New York, NY. The company has a portfolio of eleven molecules, many in late-stage clinical development, targeting therapeutic areas such as oncology, autoimmune disorders, cardio-renal diseases, and infectious diseases. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Ian Ying Woo
| Unternehmen | Position | Ende |
|---|---|---|
| PRENETICS GLOBAL LIMITED | Direktor/Vorstandsmitglied | - |
Lazard Frères & Co. LLC
 Lazard Frères & Co. LLC Investment ManagersFinance Provides corporate advisory, capital market, and asset management services | Corporate Officer/Principal | - |
Ausbildung von Ian Ying Woo
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
98
Beziehungen ersten Grades
10
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 10 |
|---|---|
Lazard Frères & Co. LLC
Lazard Frères & Co. LLC Investment ManagersFinance Provides corporate advisory, capital market, and asset management services | Finance |
Tufts University
 Tufts University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Columbia Business School
 Columbia Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Graduate School of Arts & Sciences (Columbia University )
 Graduate School of Arts & Sciences (Columbia University ) Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Everest Medicines Ltd.
 Everest Medicines Ltd. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company which develops and commercializes therapies to address critical unmet medical needs | Health Technology |
Everest Medicines (US) Ltd.
Everest Medicines (US) Ltd. Pharmaceuticals: MajorHealth Technology Part of Everest Medicines Ltd., Everest Medicines (US) Ltd. is a biopharmaceutical company focused on developing and commercializing pharmaceutical products that address unmet medical needs for patients in Asian markets. The company is based in New York, NY. The company has a portfolio of eleven molecules, many in late-stage clinical development, targeting therapeutic areas such as oncology, autoimmune disorders, cardio-renal diseases, and infectious diseases. | Health Technology |
CBC Group Co., Ltd. | |
I-Mab
 I-Mab Pharmaceuticals: MajorHealth Technology Develops and manufactures medicines for cancer and autoimmune diseases | Health Technology |
Everest Medicines II Ltd.
Everest Medicines II Ltd. Pharmaceuticals: MajorHealth Technology Develops and commercializes pharmaceutical products | Health Technology |
Prenetics Global Ltd.
 Prenetics Global Ltd. Financial ConglomeratesFinance Manufactures diagnostic testing equipment | Finance |
